Optical and magnetic resonance imaging as complementary modalities in drug discovery

Future Medicinal Chemistry

Volumn 2, Issue 3, 2010, Pages 317-337

  Sandanaraj, Britto S ^b   Kneuer, Rainer ^a   Beckmann, Nicolau ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CASPASE 3; CATHEPSIN; CD40 LIGAND MONOCLONAL ANTIBODY; CETUXIMAB; COPPER 64; CYANINE DYE 5; DACLIZUMAB; DEXAMETHASONE; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; INDOCYANINE GREEN; LIPOCORTIN 5; LIPOSOME; PACLITAXEL; RITUXIMAB; TECHNETIUM 99M; TRASTUZUMAB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DISTRIBUTION; ENZYME ACTIVITY; FLUORESCENCE IMAGING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; ISOTOPE LABELING; LUNG CANCER; NANOPROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE; TREATMENT RESPONSE;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FLUORESCENT DYES; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MOLECULAR STRUCTURE; PROTEINS;

EID: 77953419959     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.175     Document Type: Review

References (98)

1. Rudin M, Beckmann N, Rausch M. Magnetic resonance imaging in biomedical research: Imaging of drugs and drug effects. Meth. Enzymol. 385, 240-256 (2004).
2. 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. Cancer Res. 63(22), 7609-7612 (2003).
3. Hamstra DA, Lee KC, Tychewicz JM et al. The use of F-19 spectroscopy and diffusionweighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol. Ther. 10(5), 916-928 (2004).
4. 19F- magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. Anticancer Drugs 15(3), 229-233 (2004).
5. Reid DG, Murphy PS. Fluorine magnetic resonance in vivo: A powerful tool in the study of drug distribution and metabolism. Drug Discov. Today 13(11-12), 473-480 (2008).
6. Griffiths JR, Glickson JD. Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy. Adv. Drug Deliv. Rev. 41(1), 75-89 (2000).
7. Artemov D, Solaiyappan M, Bhujwalla ZM. Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. Cancer Res. 61(7), 3039-3044 (2001).
8. Kato Y, Okollie B, and Artemov D. Noninvasive H-1/C-13 magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn. Reson. Med. 55(4), 755-761 (2006).
9. Rudin M, Beckmann N, Sauter A. In vivo pharmacokinetics using MRS [2]. NMR Biomed. 12(6), 404 (1999).
10. Rudin M, Beckmann N, Porszasz R, Reese T, Bochelen D, Sauter A. In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives [Review], NMR Biomed. 12(2), 69-97 (1999).
11. Beckmann N, Laurent D, Tigani B, Panizzutti R, Rudin M. Magnetic resonance imaging in drug discovery: Lessons from disease areas. DrugDiscov. Today 9(1), 35-42 (2004).
12. Beckmann N, Mueggler T, Allegrini PR, Laurent D, Rudin M. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat. Rec. 265(2), 85-100 (2001).
13. Aime S, Carrera C, Delli CD, Geninatti CS, Terreno E. Tunable imaging of cells labeled with MRI-PARACEST agents. Angew. Chem. Int. Ed. Engl. 44(12), 1813-1815 (2005).
14. Woods M, Donald EWC, Sherry AD. Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem. Soc. Rev. 35(6), 500-511 (2006).
15. Zhou. J, Payen J-F, Wilson DA, Traystman RJ, Van Zijl PCM. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat. Med. 9(8), 1085-1090 (2003).
16. Aime S, Delli CD, Terreno E. Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. Angew. Chem. Int. Ed. Engl. 44(34), 5513-5515 (2005).
17. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 53(5), 999-1005 (2005).
18. Mani V, Briley-Saebo KC, Itskovich VV, Samber DD, Fayad ZA. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn,. Reson. Med. 55(1), 126-135 (2006).
19. Takaoka Y, Sakamoto T, Tsukiji S et al. Self-assembling nanoprobes that display off/ on F-19 nuclear magnetic resonance signals for protein detection and imaging. Nat. Chem. 1(7), 557-561 (2009).
20. 13C imaging-a new diagnostic platform. Eur. Radiol. 16(1), 57-67 (2006).
21. Moller HE, Chen XJ, Saam B et al. MRI of the lungs using hyperpolarized noble gases. Magn. Reson. Med. 47(6), 1029-1051 (2002).
22. 129Xe MRI: a viable functional lung imaging modality? Eur. J. Radiol.64(3), 335-344 (2007).
23. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. C-13 MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized C-13-labeled glutamine. Magn. Reson. Med. 60(2), 253-257 (2008).
24. Weisskoff RM, Chesler D, Boxerman JL, Rosen BR. Pitfalls in MR measurement of tissue blood flow with intravascular tracers: Which mean transit time? Magn. Reson. Med. 29(4), 553-558(1993).
25. Rudin M, Beckmann N, Sauter A. Analysis of tracer transit in rat brain after carotid artery and femoral vein administration using linear system theory. Magn. Reson. Imaging 15(5), 551-558(1997).
26. Rudin M, Pedersen B, Umemura K, Zierhut W. Determination of rat heart morphology and function in vivo in two models of cardiac hypertrophy by means of magnetic resonance imaging. Basic Res. Cardiol. 86(2), 165-174 (1991).
27. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs -will they model the next 100? Nat. Rev. Drug Discov. 2(1), 38-51 (2003).
28. Schafer R, Wiskirchen J, Guo K et al. Aptamer-based isolation and subsequent imaging of mesenchymal stem cells in ischemic myocard by magnetic resonance imaging. Rofo 179(10), 1009-1015 (2007).
29. Schmieder AH, Winter PM, Caruthers SD et al. Molecular MR imaging of melanoma angiogenesis with α(nu) β(3)-targeted paramagnetic nanoparticles. Magn. Reson. Med. 53(3), 621-627 (2005).
30. 3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vase. Biol. 26(9), 2103-2109 (2006).
31. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96(3), 327-336 (2005).
32. Schuppli CA, Fraser D, McDonald M. Expanding the three Rs to meet new challenges in humane animal experimentation. Altern. Lab. Anim. 32(5), 525-532 (2004).
33. Beckmann N, Cannet C, Babin AL et al. In vivo visualization of macrophage infiltration and activity in inflammation using MRI. WIREs Nanomed. Nanobiotechnol. 1, 272-298 (2009).
34. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2(7), 566-580 (2003).
35. Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and. clinical endpoints for more efficient drug development. J. Clin. Pharmacol. 40(12 II), 1419-1427 (2000).
36. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41, 347-366 (2001).
37. Pien HH, Fischmari AJ, Thrall JH, Sorensen AG. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov. Today 10(4), 259-266 (2005).
38. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. 21(7), 1404-1411 (2003).
39. DiMiasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20(Suppl. 3), 1-10 (2002).
40. Xie J, Schultz PG. A chemical toolkit for proteins - an expanded genetic code. Nat. Rev. Mol. Cell Biol. 7(10), 775-782 (2006).
41. Link AJ, Mock ML, Tirrell DA. Noncanonical amino acids in protein engineering. Curr. Opin. Biotechnol. 14(6), 603-609 (2003).
42. Caravan P, Das B, Dumas S et al. Collagentargeted MRI contrast agent for molecular imaging of fibrosis. Angew. Chem. Int. Ed. Engl. 46(43), 8171-8173 (2007).
43. Lee CM, Jeong HJ, Kim EM et al. Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo. Magn. Reson. Med. 62(6), 1440-1446 (2009)
44. Dothager RS, Flentie K, Moss B, Pan MH, Kesarwala A, Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr. Opin. Biotechnol. 20(1), 45-53 (2009).
45. Luker KE, Luker GD. Applications of bioluminescence imaging to antiviral research and therapy: Multiple luciferase enzymes and quantitation. Antiviral Res. 78(3), 179-187 (2008).
46. Stell A, Belcredito S, Ramachand ran B et al. Multimodality imaging: novel pharmacological applications of reporter systems. Q. J. Nucl. Med. Mol. Imaging 51(2), 127-138 (2007).
47. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: The evolution of whole-body photonic imaging. Nat. Biotechnol. 23(3), 313-320 (2005).
48. Ma R, Taruttis A, Ntziachristos V. Razansky D. Multispectral optoacoustic tomography (MSOT) scanner for whole-body small animal, imaging. Opt. Express 17(24), 21414-21426 (2009)
49. Razansky D, Distel Mi, Vinegoni C et al. Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nat: Photonics 3(7), 412-417 (2009)
50. Chandran SS, Dickson KA, Raines RT. Latent fluorophore based on the trimethyl lock. J. Am. Chem. Soc. 127(6), 1652-1653 (2005).
51. Lavis LD, Chao TY, Raines RT. Latent blue arid red fluorophores based on the trimethyl lock. Chembiochem 7(8), 1151-1154 (2006)
52. Cai SX, Zhang H-Z, Guastella J, Drewe J, Yang W, Weber E. Design and synthesis of rhodamine 110 derivative and caspase-3 substrate for enzyme and cell-based fluorescent assay. Bioorg. Med. Chem. Lett. 11(1), 39-42 (2001).
53. Bullok K, Piwnica-Worms D. Synthesis and characterization of a small, membranepermeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. J. Med. Chem. 48(17), 5404-5407 (2005)
54. Bullok KE, Maxwell D, Kesarwala AH et al. Biochemical and in vivo characterization of a small, membrane-permeant, caspaseactivatable far-red fluorescent peptide for imaging apoptosis. Biochemistry 46(13), 4055-4065 (2007).
55. Baruch A, Jeffery DA, Bogyo M. Enzyme activity-it's all about image. Trends Cell Biol. 14(1), 29-35 (2004)
56. Jeffery DA, Bogyo M. Chemical proteomics and its application to drug discovery. Curr. Opin. Biotechnol. 14(1), 87-95 (2003).
57. Speers AE, Cravatt BF. Chemical strategies for activity-based proteomics. Chembiochem 5(1), 41-47 (2004).
58. Blum G, Von DG, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3(10), 668-677 (2007).
59. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol. Chem. 385 (11), 1017-1027 (2004).
60. Kelly KA, Waterman P, Weissleder R. In vivo imaging of molecularly targeted phage. Neoplasia 8(12), 1011-1018 (2006)
61. Edgington LE, Berger AB, Blum G, Albrow VE, Paulick MG, Lineberry N, Bogyo M. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat. Med. 15(8), 967-973 (2009).
62. Sletten EM, Bertozzi CR. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality [Review]. Angew. Chem. Int. Ed. Engl. 48(38), 6974-6998 (2009)
63. Qian H, Gu Y, Wang M, Achilefu S. Optimization of the near-infrared fluorescence labeling for in vivo monitoring of a protein drug distribution in animal model. J. Fluoresc. 19(2), 277-284 (2009).
64. Johnsson N, Johnsson K. A. fusion of disciplines: Chemical approaches to exploit fusion proteins for functional genomics. Chembiochem 4 (9), 803-810 (2003)
65. Fernandez-Suarez M, Ting AY. Fluorescent probes for super-resolution imaging in living cells. Nat. Rev. Mol. Cell Biol. 9(12), 929-943 (2008).
66. Wang L, Xie J, Schultz PG. Expanding the genetic code. Annu. Rev. Biophys. Biomol. Struct. 35, 225-249 (2006).
67. Wang L, Schultz PG. Expanding the genetic code. Angew. Chem. Int. Ed. Engl. 44(1), 34-66 (2004).
68. Wang Q, Parrish AR, Wang L. Expanding the genetic code for biological studies. Chem. Biol. 16(3), 323-336 (2009).
69. Klohs J, Grafe M, Graf K et al. In vivo imaging of the inflammatory receptor CD40 after cerebral ischemia using a fluorescent antibody. Stroke 39(10), 2845-2852 (2008).
70. Biffi S, Garrovo C, Macar P et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using timedomain near-infrared optical imaging. Mol. Imaging7(6), 272-282 (2008).
71. Hilger I, Leistner Y, Berndt A et al. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur. Radiol. 14(6), 1124-1129 (2004).
72. Lee SB, Hassan M, Fisher R et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin. Cancer Res. 14(12), 3840-3849 (2008).
73. Shan L, Hao Y, Wang S et al. Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate. Mol. Imaging 7(1), 42-49 (2008).
74. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 9(12), 1021-1029 (2007).
75. Gee MS, Upadhyay R, Bergquist H, Weissleder R, Josephson L, Mahmood U. Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment. Int. J. Cancer 121(11), 2492-2500 (2007)
76. Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17(4), 316-322 (2007)
77. Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 8(9), 772-780 (2006).
78. Kelly KA, Waterman P, Weissleder R. In vivo imaging of molecularly targeted phage. Neoplasia 8(12), 1011-1018 (2006).
79. Chang SK, Rizvi I, Solban N, Hasan T. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin. Cancer Res. 14(13), 4146-4153 (2008).
80. Backer MV, Levashova Z, Patel V et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat. Med. 13(A), 504-509 (2007).
81. Dietrich T, Perlitz C, Licha K et al. ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions. Basic Res. Cardiol. 102(4), 298-307 (2007).
82. Graf K, Dietrich T, Tachezy M et al. Monitoring therapeutical intervention with ezetimibe using targeted, near-infrared fluorescence imaging in experimental atherosclerosis. Mol. Imaging7(2), 68-76 (2008).
83. Sandanaraj BS, Gremlich HU, Krieuer R, Dawson J, Wacha S. Fluorescent nanoprobes as a biomarker for increased vascular permeability: implications in diagnosis and treatment of cancer and inflammation. Bioconjug. Chem. 21(1), 93-101 (2010).
84. Leggett J, Crozier S, Bowtell RW Actively shielded multi-layer gradient coil designs with improved cooling properties. J. Magn. Reson. 165(2), 196-207 (2003).
85. Bilgen M. Inductively-overcoupled coil design for high resolution magnetic resonance imaging. Biomed. Eng. Online 5 (2006).
86. Poirier-Quinot M, Ginefri J-C, Girard O, Robert P, Darrasse L. Performance of a miniature high-temperature superconducting (HTS) surface coil for in vivo microimaging of the mouse in a standard 1.5T clinical whole-body scanner. Magn. Reson. Med. 60(A), 917-927 (2008).
87. Ratering D, Baltes C, Nordmeyer-Massner J, Marek D, Rudin M. Performance of a 200-MHz cryogenic RF probe designed for MRI and MRS of the murine brain. Magn. Reson. Med. 59(6), 1440-1447 (2008).
88. Brau ACS, Hedlund LW, Johnson GA. Cine magnetic resonance microscopy of the rat heart using cardiorespiratory-synchronous projection reconstruction. J. Magn. Reson. Imaging20(1), 31-38(2004).
89. Tengowski MW, Kotyk JJ. Risk identification and management: MRI as a research tool in toxicology studies of new chemical entities. Prog. Drug Res. 62, 257-278 (2005).
90. Srinivasan S, Pogue BW, Jiang S etal. In vivo hemoglobin and water concentrations, oxygen saturation, and scattering estimates from near-infrared breast tomography using spectral reconstruction. Acad. Radiol. 13(2), 195-202 (2006).
91. Intes X, Ripoll J, Chen Y, Nioka S, Yodh AG, Chance B. In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green. Med. Phys. 30(6), 1039-1047 (2003).
92. Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast: after indocyanine green enhancement. Proc. Natl Acad. Sci. USA 97(6), 2767-2772 (2000).
93. Scheel AK, Backhaus M, Klose AD et al. First clinical evaluation of sagittal laser optical tomography for detection of synovitis in arthritic finger joints. Ann. Rheum. Dis. A 64(2), 239-245 (2005).
94. Benaron DA, Hintz SR, Villringer A et al. Noninvasive functional imaging of human brain using light. J. Cereb. Blood Flow Metab. 20(3), 469-477 (2000)
95. Hillman EMC, Hebden JC, Schweiger M et al. Time resolved optical tomography of the human forearm. Phys. Med. Biol.y 46(4), 1117-1130 (2001).
96. Ntziachristos V, Ripoll J, Weissleder R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Opt. Lett. 27(5), 333-335 (2002)
97. Ale A, Sarantopoulos A, Freyer M, Soehngen E, Zientkowska M, Ntziachristos V. Hybrid system for simultaneous fluorescence and x-ray computed, tomography. IEEE Trans. Med. Imaging 29(2), 465-473 (2010).
98. Biophotonics - Biomedical technology www.bioopti.cswor.ld.com/articles/ article display.htrnl?id-331922